Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Thrombosis
•
Pediatric Hematology
•
Anticoagulation
•
Pediatric Oncology
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
Related Questions
How should clinicians approach the decision to use apixaban, or other DOACs, in pediatric patients with acute lymphoblastic leukemia or lymphoma who have additional risk factors for VTE, such as obesity or a family history of thrombosis, given the negative outcome of the PREVAPIX-ALL trial?
How is your experience with point-of-care INR systems for home monitoring of vitamin K antagonists?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
What is your recommended long term management of extensive dural venous sinus thrombosis in an otherwise healthy young patient?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
What are some of the medical management strategies for pediatric extracranial AVMs?
